Navigation Links
Low levels of PYY hormone a very early indicator of type 2 diabetes
Date:3/10/2008

It may soon be possible to take a simple blood test and predict whether or not someone has low levels of a particular molecule, predisposing them to the development of Type 2 diabetes. If the test is positive, it may then be possible to use preventative treatment, slowing down, or even halting that development.

Such is the hope of scientists and clinicians at Sydneys Garvan Institute of Medical Research who have shown conclusively that people who produce low levels of the molecule PYY have a higher risk of developing Type 2 diabetes and obesity.

The findings were published online on 4 March in the prestigious International Journal of Obesity.

It is already known that the hormone PYY, which is released from the gut after a meal, creates a feeling of satiety. When PYY is in oversupply, it prevents diet-induced obesity in mice.

Professor Herbert Herzog, Director of Garvans Neuroscience Program, and an expert on appetite, says that the new findings are important in that they show a metabolic defect before the presence of any disease or manifestation of weight gain. We can now see that low PYY levels after eating are a very early predictor of the development of obesity and Type 2 diabetes, he said.

Professor Lesley Campbell, Director of Diabetes Services at St. Vincents Hospital and a senior member of Garvans Diabetes and Obesity Clinical Studies group, has been researching genetic factors in the development of Type 2 diabetes for over 10 years. Specifically, her research looks at people before they get the disease, the contributing factors, and the effects of the diabetes.

Professor Campbell has already published findings that insulin resistant people, with a family history of Type 2 diabetes, have low levels of PYY. In earlier studies we hinted at the fact that before any of the abnormalities of diabetes are present, people already have an abnormality of satiety, marked by the lack of the secretion of this PYY
'/>"/>

Contact: Alison Heather
A.heather@garvan.org.au
61-292-958-128
Research Australia
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Estrogen Levels in Blood Predict Breast Cancers Return
2. Atypical protein kinase C stabilizes SRC-3 levels in breast cancer cells
3. Moderate Aerobic Fitness Levels May Cut Stroke Risk
4. Novel link between excessive nutrient levels and insulin resistance
5. Silymarin does not affect virus activity or ALT levels in
6. In Unfolding Budget Debate, Alliance to Spotlight Flawed MedPAC Policy Guidance, Failure to Evaluate Medicaid Margins in Recommending Medicare Funding Levels
7. New findings show Enbrel significantly reduced levels of C-reactive protein
8. Low vitamin E levels associated with physical decline in elderly
9. High Levels of Stress After 9/11 Raised Heart Disease Risk
10. College Drinking Games Lead to Higher Blood Alcohol Levels
11. Tis the Season to be Jolly ... and Stress-Free: Survey Reveals Womens Stress Levels During the Holidays
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3New National Pharmaceutical Council Report Provides Guidance on Evaluating Comparative Effectiveness Studies 2Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 2Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 3Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 4Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 5New Productivity Suite From Varian Inc Increases Throughput for NMR Laboratories 14169 1New Productivity Suite From Varian Inc Increases Throughput for NMR Laboratories 14169 2New Productivity Suite From Varian Inc Increases Throughput for NMR Laboratories 14169 3DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 1DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 2DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 3DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 4DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 5DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 6Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 1Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 2Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 3Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 4Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 5Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 6Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 7Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 8